Related Experiment Video
Updated: Sep 27, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
Targeting the Enteroendocrine System for Treatment of Obesity
Emily L Miedzybrodzka1, Fiona M Gribble2, Frank Reimann1
1Wellcome Trust - MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Abstract:
Mimetics of the anorexigenic gut hormone glucagon-like peptide 1 (GLP-1) were originally developed as insulinotropic anti-diabetic drugs but also evoke significant weight loss, leading to their recent approval as obesity therapeutics. Co-activation of receptors for GLP-1 and other gut hormones which reduce food intake - peptide YY (PYY3-36), cholecystokinin (CCK) and glucose-dependent insulinotropic peptide (GIP) - is now being explored clinically to enhance efficacy. An alternative approach involves pharmacologically stimulating endogenous secretion of these hormones from enteroendocrine cells (EECs) to recapitulate the metabolic consequences of bariatric surgery, where highly elevated postprandial levels of GLP-1 and PYY3-36 are thought to contribute to improved glycaemia and weight loss.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Regulation of Food Intake
Hormonal Regulation
Regulation of the Digestive System
The effectors in this regulation system are glands and smooth muscles. Activation of...
What is the Endocrine System?
Structures of the Endocrine System

